Le Lézard
Classified in: Science and technology
Subject: FVT

NASA, SpaceX Invite Media to Crew-1 Mission Update, Target New Launch Date


WASHINGTON, Oct. 26, 2020 /PRNewswire/ -- NASA and SpaceX now are targeting 7:49 p.m. EST Saturday, Nov. 14, for the launch of the first crew rotation mission to the International Space Station as part of the agency's Commercial Crew Program.

NASA Logo.

Managers of NASA's SpaceX Crew-1 mission will hold a media teleconference at 4 p.m. EDT Wednesday, Oct. 28, to discuss the upcoming launch, including results from recent testing of the Falcon 9 Merlin engines following unexpected data SpaceX noted during a recent non-NASA launch. Audio of the teleconference will stream live on the agency's website.

Briefing participants include:

Media may ask questions via phone only. For the dial-in number and passcode, please contact the newsroom at NASA's Kennedy Space Center in Florida no later than 2 p.m. Wednesday, Oct. 28, at ksc-newsroom@mail.nasa.gov.

NASA's SpaceX Crew-1 mission will launch the agency's astronauts Michael Hopkins, Victor Glover, and Shannon Walker, along with Japan Aerospace Exploration Agency (JAXA) mission specialist Soichi Noguchi, from Launch Complex 39A at Kennedy.

Crew-1 astronauts will join the Expedition 64 crew of Commander Sergey Ryzhikov, and Flight Engineers Sergey Kud-Sverchkov and NASA astronaut Kate Rubins. The arrival of Crew-1 will increase the regular crew size of the space station's expedition missions from six to seven astronauts, adding to the amount of crew time available for research.

The Crew-1 mission will launch a few days after the Nov. 10 scheduled launch of NASA's Sentinel-6 Michael Freilich mission on a SpaceX Falcon 9 from Vandenberg Air Force Base in California, following a thorough review of launch vehicle performance.

Audio of the teleconference will stream live online at:

https://www.nasa.gov/live

For more information about the mission, visit:

https://www.nasa.gov/commercialcrew

SOURCE NASA


These press releases may also interest you

at 18:05
GlycoMimetics' product candidate uproleselan ? when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) ? was shown today in an oral presentation to break chemoresistance by dramatically and significantly reducing tumor...

at 18:00
Quanta X Technology, the parent company of QuantaDose, CEO Katie Webb suggests, "Anyone in Santa's shoes gifting a UVC device to a friend or family member needs to make sure the UV-C device is real, and they also need to understand the potential...

at 17:00
63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ?6 months of follow-up, 83% have ongoing responses...

at 16:30
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab (JNJ-64007957) for the treatment of relapsed or refractory multiple...

at 15:30
Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an interim readout to evaluate the...

at 15:05
bluebird bio, Inc. today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene therapy (beti-cel; formerly LentiGlobintm for ?-thalassemia) in patients with transfusion-dependent...



News published on 26 october 2020 at 19:24 and distributed by: